Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | ronidazole | 5756 | drug-path |
Bladder cancer | R-HSA-9700206 | map05219 | ronidazole | 5756 | drug-path |
Basal transcription factors | R-HSA-3232118 | map03022 | ronidazole | 5756 | drug-path |
Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | ronidazole | 5756 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | lorglumide | 3926 | drug-path |
Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | lorglumide | 3926 | drug-path |
Ubiquitin mediated proteolysis | R-HSA-983153 | map04120 | lorglumide | 3926 | drug-path |
Hematopoietic cell lineage | R-HSA-173752 | map04640 | lorglumide | 3926 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | lorglumide | 3926 | drug-path |
Antigen processing and presentation | R-HSA-1236975 | map04612 | lorglumide | 3926 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | lorglumide | 3926 | drug-path |
Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | lorglumide | 3926 | drug-path |
Asthma | R-HSA-444620 | map05310 | lorglumide | 3926 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | lorglumide | 3926 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | lorglumide | 3926 | drug-path |
SNARE interactions in vesicular transport | R-HSA-428625 | map04130 | lorglumide | 3926 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | lorglumide | 3926 | drug-path |
GnRH signaling pathway | R-HSA-168638 | map04912 | lorglumide | 3926 | drug-path |
Hematopoietic cell lineage | R-HSA-173752 | map04640 | enoxacin | 6234 | drug-path |
Epithelial cell signaling in Helicobacter pylori infection | 0 | map05120 | enoxacin | 6234 | drug-path |